These findings differ from the values reported in studies conducted in other countries.8In a longitudinal study with 15 children (aged 4–17 years) with mixed CMT genetic types, disease progression was observed at a rate of 1.0 CMTPedS point per year, representing a 5% change from baseline.11Moreover, a cross-sectional study5with 520 CMT patients further revealed that the total CMTPedS scores progressed consistently throughout early childhood (ages 3–10 years) and adolescence (ages 11–20 years) in CMT1A, whereas the rate of change in CMT1B, CMT2A, and CMT4C appeared to be age-specific. Here, PMP22 is linked to Charcot-Marie-Tooth disease.